Myriad Genetics Q1 Product Revenues Increase 3 Percent
The company reported revenues of $164.9 million, all of which came from its molecular testing business, beating analysts' consensus expectation.
Source: 360dx.com
📰 Bracanalysis Cdx News
Page 4 - Bracanalysis Cdx News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Bracanalysis Cdx. Real-time updates on events, politics, business and more.
FDA Approves First PARP Inhibitor for Early BRCA+ Breast Cancer
Overall survival results showing a 32% reduction in mortality with olaparib vs placebo will be presented at an upcoming EMSO virtual plenary session.
United States Bracanalysis Cdx Genetics Inc American Society Of Clinical Oncology Bracanalysis Cdx Myriad Genetics Inc European Society For Medical Oncology Virtual Plenary
Source: medscape.com
FDA OKs PARP Inhibitor as Adjuvant Therapy in Early Breast Cancer
Olaparib (Lynparza) approved for high-risk patients with germline <em>BRCA</em> mutations
Source: medpagetoday.com
Myriad Genetics Receives FDA Approval of BRACAnalysis CDx as a Companion Diagnostic for Lynparza in Early Breast Cancer
12.03.2022 - BRACAnalysis CDx is now the only germline test approved by FDA as a companion diagnostic for treatment of HER2 negative high-risk early-stage breast cancerSALT LAKE CITY, March 11, 2022 (GLOBE NEWSWIRE) - Myriad Genetics, Inc., (NASDAQ: MYGN), a ... Seite 1
Source: wallstreet-online.de
Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
FDA Approves Lynparza as Adjuvant Therapy With Myriad Genetics' CDx for BRCA-Mutated Breast Cancer
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.
Source: precisiononcologynews.com
FDA Approves Lynparza as Adjuvant Therapy With Myriad Genetics' CDx for BRCA-Mutated Breast Cancer
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.
Source: genomeweb.com
FDA Approves Lynparza as Adjuvant Therapy With Myriad Genetics' CDx for BRCA-Mutated Breast Cancer
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.
Source: 360dx.com
FDA Approves Lynparza as Adjuvant Treatment in Early-Stage, BRCA1/2-Mutated Breast Cancer
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.
Source: precisiononcologynews.com
Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference
02.03.2022 - SALT LAKE CITY, March 02, 2022 (GLOBE NEWSWIRE) - Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be participating in a fireside chat at the 42nd Annual Cowen ...
Source: wallstreet-online.de